Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eleanor Malone

London, UK
Eleanor has been editor of Scrip Intelligence since 2014. She has more than 15 years’ experience writing specialist news and analysis for and about the biopharma industry. She holds an MA in modern languages from the University of Edinburgh. Based in London, she appears regularly on TV and radio and conference panels to discuss matters related to the industry.
Advertisement
Set Alert for Articles By Eleanor Malone

Latest From Eleanor Malone

Top 10 Drugs: Biologic Blockbusters And The Biosimilar Threat

INFOGRAPHIC: maturing cancer and autoimmune biologics still top the league for global revenues, but biosimilars are snapping at their heels.

 

Biologics Commercial

Top 10 Drugs: Weighing Pharma's Golden Eggs

INFOGRAPHIC: A relatively small number of relatively costly drugs account for a sizable proportion of pharma industry revenues. But what are its biggest golden eggs, how reliant are companies on those products, and how has the situation evolved over time?

Market Intelligence Commercial

Almirall’s Dermatology Pitch Takes Shape

CEO Peter Guenter’s focus on first- and best-in-class looks like the right strategy as Spanish pharma builds critical mass in dermatology.

Sales & Earnings Strategy

Timeline: Almirall's Pivot To Dermatology

As Almirall's dermatology strategy bears commercial fruits, Scrip examines the key steps in its transformation, its recent financial performance, and its sales forecasts for innovative launches.

Strategy Companies

Novartis’s Entresto PARAGON-HF Miss Puts Large Commercial Opportunity At Risk

Entresto has narrowly failed to hit the primary endpoint in a Phase III trial in heart failure with preserved ejection fraction, a potentially lucrative indication with no approved treatments.

Clinical Trials Research & Development

GW Pharma’s Cannabidiol For Seizures One Step Closer To European Approval

The CHMP has issued a positive opinion for Epidyolex for two rare conditions. The cannabidiol product was approved in the US in 2018.

Approvals Neurology
See All
Advertisement
UsernamePublicRestriction

Register